TY  - JOUR
AU  - Ascierto, Paolo A
AU  - Dréno, Brigitte
AU  - Larkin, James
AU  - Ribas, Antoni
AU  - Liszkay, Gabriella
AU  - Maio, Michele
AU  - Mandalà, Mario
AU  - Demidov, Lev
AU  - Stroyakovskiy, Daniil
AU  - Thomas, Luc
AU  - de la Cruz-Merino, Luis
AU  - Atkinson, Victoria
AU  - Dutriaux, Caroline
AU  - Garbe, Claus
AU  - Hsu, Jessie
AU  - Jones, Surai
AU  - Li, Haocheng
AU  - McKenna, Edward
AU  - Voulgari, Athina
AU  - McArthur, Grant A
PY  - 2021
DO  - 10.1158/1078-0432.CCR-21-0809
UR  - https://hdl.handle.net/10668/27587
T2  - Clinical cancer research : an official journal of the American Association for Cancer Research
AB  - The randomized phase III coBRIM study (NCT01689519) demonstrated improved progression-free survival (PFS) and overall survival (OS) with addition of cobimetinib to vemurafenib compared with vemurafenib in patients with previously untreated BRAFV600...
LA  - en
KW  - Antineoplastic Combined Chemotherapy Protocols
KW  - Azetidines
KW  - Follow-Up Studies
KW  - Humans
KW  - Melanoma
KW  - Mutation
KW  - Piperidines
KW  - Proto-Oncogene Proteins B-raf
KW  - Skin Neoplasms
KW  - Vemurafenib
TI  - 5-Year Outcomes with Cobimetinib plus Vemurafenib in BRAFV600 Mutation-Positive Advanced Melanoma: Extended Follow-up of the coBRIM Study.
TY  - research article
VL  - 27
ER  -